Novel Approach to Improving Prostate Cancer Screening Among African American MenDMDavid M NanusACAlfred Clinton WinklerEPErica PhillipsKKKevin KenslerU.S. Department of Defense · 2022–2026W81XWH-22-1-0451Ending soon
The Impact of Staffing Levels on Access, Quality and Utilization: Evidence from Primary CareABAmelia BondU.S. Department of Defense · 2024–2027HT9425-24-1-1013Ending soon
A Non-Inferiority Randomized Controlled Clinical Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Consequent to MST in Male and Female Military Personnel and VeteransJDJoAnn DifedeAMAndrew McAleaveyRBRobin BrodyFSFrancis S Lee+1 moreU.S. Department of Defense · 2018–2025W81XWH-18-1-0262Recently ended
Characterizing 3'-UTR biology as a mechanism of therapy response in high risk prostate cancer.CBChristopher BarbieriLMLuigi MarchionniMRMert Rory SabuncuMLMassimo LodaU.S. Department of Defense · 2024–2025HT9425-24-1-0310Recently ended
Metabolic Regulation of mTORC1 Catalytic ActivityJBJohn BlenisU.S. Department of Defense · 2017–2020W81XWH-17-1-0118
Global Control of Ovarian Cancer Immunity by Aberrant ER Stress ResponsesJRJuan R Cubillos-RuizU.S. Department of Defense · 2016–2021W81XWH-16-1-0438
Dissecting the Role of APOBEC3 Mutagenic Proteins as Drivers of Genomic-Instability and Chemotherapy-Resistance in Urothelial CarcinomaBMBishoy Morris FaltasU.S. Department of Defense · 2017–2021W81XWH-17-1-0539
A smart soft robotic tool for semi-automated intubationBMBobak MosadeghKSKaushal ShahU.S. Department of Defense · 2022–2026W81XWH-22-1-0103Ending soon
Pharmacological Targeting of UBR5 for Breast Cancer ImmunotherapyGLGang LinXMXiaojing MaU.S. Department of Defense · 2026–2029HT9425-26-1-E178Active
Effects of Traumatic Brain Injury and Post-Traumatic Stress Disorder and Alzheimer's Disease on Brain Tau in Vietnam Veterans Using ADNIMTMichael T. LinGCGloria Chia-Yi ChiangU.S. Department of Defense · 2015–2018 · via University of Southern CaliforniaWEI1872-06
Circulating Antibody Repertoire And Blood-Brain-Barrier Impairment to explain NEuRopsychiatric symptoms of "invisible" brain injuryEGEric GoldwaserAJAbhishek JaywantU.S. Department of Defense · 2025–2029HT9425-25-1-0791Active
Investigation of UBR5 and its signaling as a novel target for breast cancer therapyXMXiaojing MaAXAizhang XuU.S. Department of Defense · 2021–2025W81XWH-21-1-0261Recently ended
Chemigenomic Drug Discovery for TuberculosisSESabine EhrtDSDirk SchnappingerU.S. Department of Defense · 2017–2022 · via Harvard UniversityW81XWH-17-PRMRP-FPA
A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate Biochemically Relapsed...STScott T. TagawaDMDavid M NanusNHNeil H. BanderPJPaul J Christos+2 moreU.S. Department of Defense · 2009–2019W81XWH-09-1-0596
Targeted TherapiesSTScott T. TagawaDMDavid M NanusU.S. Department of Defense · 2022–2026W81XWH-22-2-0018Ending soon
Urinary Biomarkers of Tuberculosis: Potential for diagnosis and beyondDWDaniel W. FitzgeraldKYKyu Y. RheeU.S. Department of Defense · 2018–2019W81XWH-18-1-0133
Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectorySCSilvia Chiara FormentiEAEleni AndreopoulouGGGiorgio Ga. InghiramiMBMelissa Boneta Davis+6 moreU.S. Department of Defense · 2021–2026W81XWH-21-2-0034Ending soon
Radiolabeled Exosomes for the Early Detection of Metastases and to Predict Breast Cancer Premetastatic NicheDCDavid C LydenU.S. Department of Defense · 2013–2018W81XWH-13-1-0249
Treatment Strategies for Mitochondrial DiseaseDCDikoma C. ShunguXMXiangling MaoU.S. Department of Defense · 2020–2021 · via Columbia University Medical Center_W81XWH-19-PRMRP-FPA
Biomarkers and Brain Mechanisms of Gulf War IllnessDCDikoma C. ShunguHSHalinder Singh MangatSVShankar VallabhajosulaXMXiangling MaoU.S. Department of Defense · 2015–2022W81XWH-15-1-0437